| Name | Olanzapine |
| Description | Olanzapine (LY170053) is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness. |
| In vitro | Olanzapine is a potent antagonist of DA and 5-HT receptors, which elevates the extracellular levels of DA metabolites, such as DOPAC, and the DA metabolite 3-methoxytyramine, in the prefrontal cortex, nucleus accumbens, and striatum of rats. Subcutaneous injections of Olanzapine (0.5-10 mg/kg) increase the levels of dopamine (DA) and norepinephrine (NE) in these regions in a dose-dependent manner. Additionally, Olanzapine significantly inhibits insulin, leading to the onset of obesity. |
| In vivo | Olanzapine interacts with several key receptors associated with schizophrenia, demonstrating nanomolar affinity for dopamine, serotonin, alpha-1 adrenergic, and cholinergic receptors. Specifically, Olanzapine selectively targets striatal dopamine in the limbic and cortical regions of the brain, exhibiting no selectivity towards dopamine receptor subtypes. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | 1eq. HCl : 31.2 mg/mL (100 mM)
DMSO : 31.2 mg/mL (100 mM)
|
| Keywords | Inhibitor | Beta Receptor | cell | Olanzapine | Apoptosis | Muscarinic acetylcholine receptor | mAChR | Dopamine Receptor | Adrenergic Receptor | damage | Mitophagy | inhibit | antipsychotic | Serotonin Receptor | neuronal | 5-HT Receptor | anticholinergic | 5-hydroxytryptamine Receptor | Autophagy | LY-170053 | Mitochondrial Autophagy | 5-HT2 | mitochondrial | SH-SY5Y | LY 170053 |
| Inhibitors Related | Adiphenine hydrochloride | Nanofin | Alverine citrate | Dapoxetine hydrochloride | Pilocarpine nitrate | CLOZAPINE N-OXIDE | Ribavirin | Octopamine hydrochloride | Choline chloride | Propoxur | Oxolinic acid | Trazodone hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
